Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Nitric oxide (NO) and methylglyoxal (MGO) play a vital part in maintaining redox homeostasis, modulating substances, and signal transduction. Fluctuations in these signaling molecules are closely associated with various pathological processes. However, due to the absence of appropriate multifunctional fluorescent sensors, concurrent identification of NO and MGO has not been achieved in inflammatory diseases. Herein, a dual-responsive near-infrared window II fluorescent probe (TPA-4T) was rationally developed to monitor NO and MGO through its distinct emission channels concurrently. Upon NO exposure, TPA-4T formed the compound TPA-4T-NO with activated fluorescence signals at 980 nm, while MGO oxidation generated TPA-4T-MGO emitting at 1065 nm. This unique dual-responsive imaging property enabled TPA-4T to concurrently monitor the elevated NO and MGO levels in subcutaneous tumors through imaging for the first time, and the dual-channel visualization in the type 2 diabetes mellitus disease model was achieved. Most importantly, TPA-4T has successfully achieved utility in drug-induced liver injury, enabling not only diagnostic visualization but also rapid drug assessment . Undoubtedly, compared with single-analyte detection, the dual-biomarker strategy may provide enhanced sensitivity and reliability for inflammation-related disease diagnosis and the screening of therapeutic agents.

Download full-text PDF

Source
http://dx.doi.org/10.1021/acsami.5c11739DOI Listing

Publication Analysis

Top Keywords

nitric oxide
8
oxide methylglyoxal
8
rapid drug
8
mgo
5
dual-channel nir-ii
4
nir-ii probe
4
probe simultaneous
4
simultaneous tracking
4
tracking nitric
4
methylglyoxal inflammation
4

Similar Publications

Background: High-density lipoprotein (HDL) function, rather than its concentration, plays a crucial role in the development of coronary artery disease (CAD). Diminished HDL antioxidant properties, indicated by elevated oxidized HDL (nHDL) and diminished paraoxonase-1 (PON-1) activity, may contribute to vascular dysfunction and inflammation. Data on these associations in CAD patients, including acute coronary syndrome (ACS), remain limited.

View Article and Find Full Text PDF

Atherosclerosis (AS) is a chronic inflammatory disease driven by endothelial dysfunction, vascular smooth muscle cell proliferation, and insufficient resolution of inflammation. Nitric oxide (NO) plays a crucial role in vascular homeostasis by promoting endothelial cell proliferation, maintaining endothelial integrity, suppressing smooth muscle cell hyperplasia, and exerting potent anti-inflammatory effects. However, clinical application of NO is hindered by its short half-life, lack of targeting, and uncontrolled release.

View Article and Find Full Text PDF

Allergic rhinitis (AR) and chronic rhinosinusitis (CRS) are common respiratory conditions that significantly impact patient health and contribute to substantial healthcare burdens. While conventional treatments offer symptom relief, many patients continue to experience persistent symptoms, side effects, or resistance to standard therapies. This highlights the growing need for novel, non-invasive, and sustainable therapeutic strategies to manage chronic airway inflammation.

View Article and Find Full Text PDF

The vascular endothelium is responsible for regulating vascular tone, maintaining fluid homeo-stasis, and preventing platelet aggregation, exhibits regulatory properties in vasorelaxation and vasoconstriction - it produces, among others, nitric oxide and endothelin. The imbalance of vasoactive molecules leads to the loss of their function, known as endothelial dysfunction. Impaired endothelial function is observed in people with metabolic disorders, often preceding the onset of the disease by several years.

View Article and Find Full Text PDF

Heart failure with reduced ejection fraction (HFrEF) is a progressive condition that is associated with high rates of morbidity, frequent hospitalizations, and significant mortality. Despite advancements in guideline-directed medical therapy (GDMT), many patients continue to be at risk for worsening heart failure (WHF). Vericiguat is a novel soluble guanylate cyclase (sGC) stimulator that targets the impaired nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway.

View Article and Find Full Text PDF